Dr. Verkh’s clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, Alliance Pharmaceutical Corporation, Alpha Therapeutic Corporation and Leukemia Intergroup at the Roosevelt Memorial Hospital at Buffalo, NY. For almost 30 years, he has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, neurology, peripheral vascular diseases, hematology, blood disorders and imaging methods. He is the author and co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market.

Dr. Verkh is responsible for worldwide regulatory and clinical development at Stemedica.  Under his leadership, Stemedica obtained several INDs for clinical trials in the United States, emergency INDs from the FDA and approval from Switzerland’s regulatory authority for compassionate treatment. In addition to directing Stemedica’s clinical trials within the United States, Dr. Verkh has assisted foreign regulatory agencies to establish guidelines for stem cell technologies in medicine in support of their respective clinical trials. He also assists in organizing and supervising clinical trials outside the United States utilizing Stemedica technology.